Immunoglobulin Market to Earn USD 24.98 Billion in Size By 2032

adminJanuary 11, 2024

The global immunoglobulin market size was estimated at US$ 13.36 billion in 2023 and is projected to reach US$ 24.98 billion by 2032, indicating a CAGR of 7.20% from 2023 to 2032.

Key Takeaways

North America contributed more than 46% market share in 2022.
Asia-Pacifica is estimated to witness the fastest CAGR between 2023 and 2032.
By application, the hypogammaglobulinemia segment has held the largest market share of 38% in 2022.
By application, the immunodeficiency disease segment is anticipated to grow at a remarkable CAGR of 9.1% between 2023 and 2032.
By product, the IgA segment generated over 41% of market share in 2022.
By product, the IgG segment is expected to expand at the fastest CAGR over the projected period.
By mode of delivery, the Intravenous segment had the largest market share of 66% in 2022.
By mode of delivery, the subcutaneous segment is expected to expand at the fastest CAGR over the projected period.

The Immunoglobulin market is a dynamic sector within the pharmaceutical and healthcare industry that primarily deals with the production and distribution of immunoglobulin products. Immunoglobulins, also known as antibodies, play a crucial role in the immune system, defending the body against various infections and diseases. The market encompasses a range of immunoglobulin therapies derived from human plasma, providing treatment solutions for a diverse array of medical conditions.

Immunoglobulin Market Size 2023 To 2032

Region Snapshot

The Immunoglobulin market exhibits a global presence, with a widespread distribution of manufacturing facilities and a robust supply chain network. Key regions contributing significantly to the market include North America, Europe, Asia-Pacific, and the rest of the world. Each region has its unique regulatory framework, impacting the production, distribution, and consumption of immunoglobulin products.

Get a Sample: https://www.precedenceresearch.com/sample/3646

Growth Factors:

The growth of the Immunoglobulin market is fueled by increasing awareness of immunodeficiency disorders, autoimmune diseases, and neurological conditions that require immunoglobulin therapies. Advancements in biotechnology and the development of novel immunoglobulin products further propel market growth. Additionally, a growing aging population and rising incidences of chronic diseases contribute to the expanding market size.

Immunoglobulin Market Scope

Report Coverage	Details
Growth Rate from 2023 to 2032	CAGR of 7.20%
Market Size in 2023	USD 13.36 Billion
Market Size by 2032	USD 24.98 Billion
Largest Market	North America
Base Year	2022
Forecast Period	2023 to 2032
Segments Covered	By Application, By Product, and By Mode of Delivery
Regions Covered	North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa

Drivers:

Several factors drive the Immunoglobulin market forward. Rising investments in research and development activities, coupled with the approval of new immunoglobulin therapies, drive market expansion. The increasing prevalence of primary immunodeficiency disorders and the expanding applications of immunoglobulins in various therapeutic areas are significant drivers shaping the market landscape.

Opportunities:

Opportunities within the Immunoglobulin market lie in the exploration of new indications for immunoglobulin therapies, expanding product portfolios, and tapping into emerging markets. Collaborations between pharmaceutical companies and research institutions present opportunities for innovative product development, while the adoption of advanced manufacturing technologies enhances production efficiency.

Challenges:

Despite the growth prospects, the Immunoglobulin market faces challenges such as stringent regulatory requirements, high production costs, and potential supply chain disruptions. Issues related to the collection and processing of human plasma, coupled with concerns about product safety and efficacy, pose challenges to market players.

Competition Landscape:

The Immunoglobulin market is characterized by intense competition among key players, including pharmaceutical companies, biotechnology firms, and plasma collection centers. Major companies engage in strategic initiatives such as mergers, acquisitions, and partnerships to strengthen their market position. Continuous efforts to enhance product quality, ensure a sustainable supply of plasma, and expand geographic reach contribute to the competitive dynamics of the Immunoglobulin market.

Recent Developments

In 2023, Everest Medicines gained approval from the Hainan Medical Products Administration for clinical use of Nefecon, a primary immunoglobulin A nephropathy (IgAN) drug, in China. This milestone marks progress in addressing IgAN, a condition affecting the kidneys, enhancing treatment options for patients in the region.
In 2022, Grifols secured approval from European Union member state health authorities and the United Kingdom for XEMBIFY, a groundbreaking 20% subcutaneous immunoglobulin (SCIG). This innovative treatment is authorized for addressing primary and specific secondary immunodeficiency, marking a significant advancement in therapeutic options for these conditions.
In 2021, Octapharma USA’s investigational new drug (IND) application for a phase three clinical trial assessing the efficacy and safety of Octagam 10% [Immune Globulin Intravenous (Human)] therapy in severe COVID-19 patients received authorization from the U.S. Food and Drug Administration (FDA).